COVID-19 vaccine reaches phase-2 trials in China
Xinhua |
Updated: 2020-06-20 21:11
Share
Share - WeChat
BEIJING - An inactivated COVID-19 vaccine candidate developed by the Institute of Medical Biology under the Chinese Academy of Medical Sciences has entered phase-2 clinical trials in China, the Science and Technology Daily reported Saturday.
The phase-2 trials, which further evaluate the immunogenicity and safety of the vaccine in humans, are conducted in the southwestern province of Yunnan.
So far, five COVID-19 vaccine candidates have been approved for clinical trials in China, accounting for 40 percent of the total vaccines in clinical trials worldwide, according to the Ministry of Science and Technology.
- Shandong apple pickers find new fame as influencers
- Ferry links mark 25-year travel milestone
- Cooperation can boost cross-Strait integration
- Global experts hail Xi's people-centered message
- Trips promote equality and coexistence
- Interest in Turkiye soars among Chinese tourists after introduction of visa-free entry
